Academic Press Intracellular Signalling Proteins: Volume 116 (Advances in Protein Chemistry and Structural Biology, Volume 116)

Product Description Intracellular Signalling Proteins, Volume 116, presents an overview of the current developments in mechanisms of intracellular signaling and involvement of these mechanisms in the development of a number of disorders and diseases. Opportunities for targeting the intracellular signaling cascades for benefiting patients are also discussed, along with chapters that focus on Voices from the Dead: The Complex Language of Dead Cells, Nucleobindins and Encoded Peptides: From Cell Signalling to Physiology, Estrogen Receptor Signaling Mechanisms, Intracellular Signaling of the AMP-Activating Protein Kinase, the Relationship between Mitofusin 2 and Cancer, Molecular Signaling in Bone Cells: Regulation Cell Differentiation and Survival, and more. Describes advances in the discovery and application of therapeutics that target intracellular signaling mechanisms Targeted to a very wide audience of specialists, researchers and students Contains timely chapters written by well-renowned authorities in their field Includes a number of high quality illustrations, figures and tables Review Promotes further research in the mechanisms of intracellular communication and in the discovery of new therapeutics About the Author Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2010 Dr. Donev was appointed Senior Lecturer in Swansea University. Currently he is Head of Research at MicroPharm Ltd, UK and Director of Biomed Consult, UK. He has published more than 60 research papers, has chaired scientific meetings in Molecular Medicine and given plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on design of antibody-based oral treatment of pathological conditions of the colon and small intestines.